ALCON

Analysis before buying or selling Alcon shares

Trade Alcon shares!

BUY

SELL

77% of retail CFD accounts lose money - eToro.com

Chart provided by Tradingview

If you are planning to start trading the Alcon share price online, we suggest helping you set up your various analyzes of this stock. Through this article dedicated to this value, we will bring you all the knowledge necessary for the realization of your analyzes of its course as a complete and detailed presentation of this company and its main sources of income, a presentation of its direct competitors in the market or from its most important partners. In another section, we will also explain how to successfully complete your fundamental analysis of this title with the study of good publications and news.

Can I receive dividends when I buy Alcon shares?

Yes

ISIN code: CH0432492467

Ticker: SWX: ALC

Index or market: SMI

How to buy and sell Alcon shares with eToro?

Open an account by clicking here

Deposit Funds

Search Alcon (SWX: ALC)

Buy/Sell Alcon shares

77% of retail CFD accounts lose money - eToro.com

Elements to consider before selling or buying Alcon shares

Analysis N°1

In particular, we will keep an eye on the development of new products by Alcon and, as such, on its investments in research and development and on obtaining legal marketing authorizations.

Analysis N°2

Of course, we will follow the competition in this sector of activity with interest and we will note in particular the evolution of the market shares of each of its major players or the release of new products and the arrival of new competitors. The data concerning the development of products in direct competition with Alcon products are particularly to be followed very closely as part of this analysis.

Analysis N°3

Strategic operations such as partnerships, disposals or acquisitions of subsidiaries are also key elements of fundamental analysis and must be known to traders.

Analysis N°4

The group communicates fairly regularly about its growth strategy and its development plans. These data are particularly interesting if you want to assess the group's ability to keep its commitments and therefore its seriousness with regard to investors.

Analysis N°5

Finally, we can of course consult the evolution of the turnover and profits of the company with the annual and quarterly results or even the evolution of the dividend of this action over time

Analysis before buying or selling Alcon shares

Buy Alcon CFD shares

Sell Alcon CFD shares

77% of retail CFD accounts lose money - eToro.com

General presentation of Alcon

As an investor, you must also have a perfect knowledge of Alcon and its specificities before you start trading in this security. This requires in particular a good knowledge of the main products marketed by this company and its main sources of income.

The Alcon group is a Swiss company which operates in the pharmaceutical sector. More specifically, this company is currently the world leader in the design, production and sale of eye care products.

To better understand the activities of this company, we can divide them into different categories according to the share of turnover they generate and in this way:

Ophthalmic surgical products and equipment represent 56.7% of the group's turnover with consumables, implantable products or even surgical equipment intended for the treatment of cataracts, retinal diseases, glaucoma and refractive errors.
Vision care products generate 43.3% of the company's turnover with contact lenses, eye care products, eye drops or ophthalmic ointments.

Currently, the Alcon group owns and operates 18 different production sites around the world.

From a geographic point of view, Alcon achieves only 0.8% of its turnover in Switzerland. Its largest market is the American market with 41.5% of turnover. Next comes Japan with 8.9% of turnover and the rest of the world for 48.8%.

Photo credits: ©conectus/123RF.COM

The major competitors of Alcon

Now let's find out who are Alcon's most important competitors in its industry with the most profitable companies in this segment:

Bausch and Lomb

This American company is currently the world number one in medical ophthalmology and optics. It was created in Germany in 1853 before migrating to the United States. This company notably supplies the US Navy with binoculars and telescopes, optical glasses, photographic lenses, microscopes and more recently, a range of eye care products.

Reckitt Benckiser

this British company is another competitor to Alcon and specializes in the manufacture and sale of cleaning products and pharmaceuticals. It is the result of the merger between Reckitt & Colman and Benckiser in 1999 and is currently the world leader in the segment of household cleaning products.

Théa

Finally, the French company Théa is also a serious competitor of Alcon, this time specializing in pharmacological products in the ophthalmology segment.

The major partners of Alcon

The Alcon group has also based its growth strategy on the implementation of various partnerships with large companies. We therefore invite you to discover two concrete examples of this type of alliance, to help you understand its importance as part of your strategies.

Google

First of all, Google decided, in 2014, to make life easier for diabetics by offering them the possibility of measuring their blood sugar level thanks to smart contact lenses and thus position themselves in the connected health segment. It is within the framework of this project that Google signed a strategic partnership with the company Alcon which was then a subsidiary of the Novartis group.

Royal Philips

A little later, Alcon also signed a major partnership with the world leader in health technology Royal Philips by giving it access to its digital platform Philips HealthSuite as part of the development of Alcon Smart Suite which is an innovative eye care platform developed to streamline, simplify and improve cataract surgery for surgeons and patients.

Workiva

Even more recently, in 2020, the Alcon group signed a strategic partnership with Workiva, a leading American platform for connected reporting and compliance. Alcon will be able to use the platform of this company in order to build and develop the compliance processes relating to its global audit, enterprise risk management or ERM and Sarvanes-Oxley or SOX law.

Trade Alcon shares!

77% of retail CFD accounts lose money. This is an advert for trading CFDs on eToro

Frequently Asked Questions

When did Alcon become a company independent of Novartis?

It was in 2019 that Alcon resumed its independence from Novartis, of which it was previously a subsidiary. Following this separation from its parent company, it thus benefited from an independent stock exchange listing. From that moment, Alcon's shares were available on the SIX Swiss Exchange market, but also on the NYSE market in New York under the acronym ALC.

How to predict the evolution of the Alcon share price?

A good anticipation of future movements in the Alcon share price requires above all a quality technical analysis using the indicators available on the stock charts, but also a complete fundamental analysis and therefore taking into account all publications and news from this company and its sector of activity.

Is it possible to trade Alcon shares directly online?

If you do not want to buy Alcon securities directly, know that you can speculate directly on the price fluctuations of this share thanks to CFD contracts or contracts on the difference. These contracts are indeed accessible to you from a simple online trading platform provided by a broker.

Trade Alcon shares!

eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFDs.

Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 77% of retail CFD accounts lose money. You should consider whether you can afford to take the high risk of losing your money.

Past performance is not an indication of future results. Trading history presented is less than 5 complete years and may not suffice as basis for investment decision.

Copy trading is a portfolio management service, provided by eToro (Europe) Ltd., which is authorised and regulated by the Cyprus Securities and Exchange Commission.

Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.

eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro.